Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma

pharmafile | December 7, 2020 | News story | Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis 

Novartis has taken the opportunity at the 2020 American Society of Hematology Annual Meeting & Exposition (ASH) to unveil promising new efficacy data for its CAR-T therapy Kymriah (tisagenlecleucel) in the treatment of several forms of advanced lymphoma.

In an interim analysis of the fiundings from the Phase 2 ELARA study, Kymriah generated a complete response rate of 65% in patients with relapsed or refractory (r/r) follicular lymphoma (FL).

Patients taking part in the study continued to experience relapse or refractory disease after receiving a median of four prior therapies before being treated with Kymriah. Following at least three months follow-up, the therapy recorded an overall response rate (ORR) of 83% in this population.

In a 40-month median follow-up of the separate Phase 2 JULIET study, one third of patients with r/r diffuse large B-cell lymphoma (DLBCL) receiving Kymriah saw their disease halted for at least two years.

In the evaluable 97 patients taking part in this study, there were no new safety signals reported; though there were three deaths in the trial, all were attributed to progressive disease and none were found to be treatment-related.

“For people who have follicular lymphoma that continues to relapse or does not respond after treatment with many lines of therapy, response to therapy becomes less likely with each additional treatment,” said Dr Nathan H Fowler, Department of Lymphoma and Myeloma, Division of Cancer Medicine at the MD Anderson Cancer Center. “We are encouraged by these interim results from the ELARA trial, as there is a great need for potentially definitive options and an alternative to stem cell transplant. We look forward to continuing to learn more about how Kymriah may provide benefit for these patients.”

Matt Fellows

Related Content

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …


AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the …

Novartis announce digital collaboration with HPE

Swiss pharma company, Novartis, has announced a collaboration with Hewlett Packard Enterprise (HPE), to accelerate …

Latest content